Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
  • Minimal Market Reaction To Supreme Court Patent Rejection For Dx Tests 0 comments
    Mar 21, 2012 6:15 PM

    Diagnostics Stocks Are Relatively Calm After Patent News: But Patents Still Matter

    The Supreme Court Ruling threw out two process patents on diagnostic tests because they were based on the laws of nature and that they were merely telling doctors of a new scientific discovery.In the WSJ article some expressed big concerns:

    "Michael R. Samardzija, an intellectual-property lawyer at Bracewell & Giuliani, who has represented diagnostic test makers and MD Anderson Cancer Center in Houston, "It's a major shift and will have profound effects on personalized medicine, and makes it a lot more difficult for diagnostic-test makers to claim their new products are patent-eligible".

    The Biotechnology Industry Organization expressed "surprise and disappointment" in the ruling. "We are concerned that it introduces new and confusing concepts into the traditional body of patent law," the group said in a statement. Oral arguments in the case appeared to go well for Prometheus, while the Obama administration had urged the court to adopt a position that was largely favorable to medical-testing companies."

    As of 2p trading Dx and Tools stocks showed little overall reaction with NASDAQ up 0.21%. Myriad Genetics (MYGN $23.39) , the focus stock of the patent issue is down 3.95% on higher than normal volume.The stock has fully recovered from past downdrafts from their patent concerns and the stock is near its 2 year high.

    Although diagnostics tools and diagnostics stocks have not participated in the biotech bull market as dramatically as biopharmaceuticals,they are still doing well YTD. Today stocks we track in the sector are relatively flat with two losers: Cepheid (CPHD $41.30) down 1.64%, and Sequenom (SQNM $3.95) down 1.86% and one winner Orasure (OSUR $11) up 3.77%. Since the article expressed concern about personalized medicine as a trend you would expect more volatility but Genomic Health (GHDX $30.52) a molecular diagnostic Company focused in personalized treatment for cancer is up 0.63%.

    Back to biopharma a clinical stage immunotherapy Company Galena(GALE $2.66) announced a patent allowance yesterday and the stock rocketed up 36% today.The Company was formerly known as RXi Pharmaceuticals and changed its name on Sep 26 when it merged and separated into two companies one with the RNAi focus and Galena that had the cancer immunotherapy clinical pipeline and Neuvax, a targeted cancer therapy.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.